Addressing the Poor Prognosis of Anaplastic Thyroid Tumors
Yuliya Mikheeva, MD, PhD, of Saint Petersburg State University, discusses the prognosis of patients with anaplastic thyroid cancer.
According to Mikheeva, anaplastic thyroid cancer is a very aggressive cancer, accounting for approximately 2% of all thyroid carcinomas. Without treatment, life expectancy is approximately 6 weeks from diagnosis. With treatment, the survival rate increases by 3 to 5 months.
Treatment is a multimodal approach including surgery, radiotherapy, and chemotherapy. For patients with a BRAF mutation, there is an opportunity to be treated with a targeted therapy, which may increase survival, according to Mikheeva.
0:08 | Anaplastic thyroid cancer is very an aggressive cancer. Among thyroid carcinomas, it accounts for about 2% of cases. The prognosis of treatment is very poor. We only have about 6 weeks from the diagnosis without treatment. And with multimodal approaches, which includes surgery, radiotherapy and chemotherapy, the survival rate increases by 3 to 5 months. That's why it is very aggressive and with poor prognosis. And the patients who have a BRAF mutation, they have an opportunity to be treated with a new targeted therapy. That's why our anti-BRAF is a good choice for these patients, and it can increase their survival.
Anticipating Novel Options for the RAI-Refractory DTC Armamentarium
May 15th 2023In season 4, episode 6 of Targeted Talks, Warren Swegal, MD, takes a multidisciplinary look at the RAI-refractory differentiated thyroid cancer treatment landscape, including the research behind 2 promising systemic therapy options.
Listen
